Cardiovascular outcome studies will provide data essential for regulatory approval and insurance coverage decisions
Regular check-ins with your healthcare provider can help assess progress, make any necessary adjustments, and address any concerns
TRUE or FALSE: Once you start GLP-1s, youre on them for life FALSE: Although some people may need to stay on medication long term in order to maintain the amount of weight loss they achieved through GLP-1s, theres no one-size-fits-all approach
265,266 When GLP-1 binds to its receptors in the hypothalamus, it activates specific neurons, including those that promote satiety (POMC/CART neurons) and inhibits those that induce hunger (NPY/AgRP neurons), thereby enhancing the feeling of fullness and reducing food intake
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Diabetologia 55 , 30943103
